MedTrace Logo

Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

NCT06572813 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-01-10

No results posted yet for this study

Summary

This is an single-center, prospective, open-label clinical trial, to explore the safty and efficacy of combination of Bortezomib, Sindilizumab, and mFOLFIRINOX Chemotherapy (oxaliplatin, fluorouracil, irinotecan, leucovorin) in metastatic pancreatic cancer

Conditions

  • Pancreas Cancer

Interventions

DRUG

Bortezomib Injection

Bortezomib Injection, a kind of chemotherapy drug

DRUG

Sintilimab

PD-1 antibody

DRUG

mFOLFIRINOX

Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Tingbo Liang · Zhejiang University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2026-09-01
Completion
2028-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06572813 on ClinicalTrials.gov